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Edited by Angel NebredaAbstract Phenobarbital (PB) induction of CYP2B, a represen-
tative target gene of constitutive androstane receptor (CAR), has
been observed to be attenuated in preneoplastic lesions of rat li-
ver; however, molecular basis for this attenuation is poorly
understood. In this report, we provide evidence indicating that
the CAR expressed in the hepatic preneoplastic lesions of rats
and mice was resistant to nuclear translocation and transactiva-
tion of the PB-responsive enhancer module upon PB treatment.
These observations suggest that the attenuation of the induction
of CYP2B by PB in hepatic preneoplastic lesions is evidently a
consequence of impaired nuclear translocation of CAR.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Nuclear receptor; Chemical carcinogenesis;
Transactivation; Phenobarbital-responsive enhancer module1. Introduction
Nuclear receptors play a pivotal role in the expression of a
battery of genes involved in the detoxiﬁcation of xenobiotics.
Constitutive androstane receptor (CAR, NR1I3) is a nuclear
receptor originally found to regulate the transcription of the
cytochrome P450 (CYP) 2B subfamily [1,2], which is induced
most signiﬁcantly by phenobarbital (PB) in the rat liver. It
has recently come to be understood that CAR governs not
only CYP2B but other drug metabolizing enzymes and trans-
porters as well, including CYP3A, CYP2C, UGT1A1, GSTA1,
OATP2 and MRP2 (see review in [3]), suggesting a multi-
functionality for this receptor. CAR translocates from the
cytoplasm to the nuclear compartment in a PB-dependent
manner [4], although to date there is no evidence that PB acts
as a direct ligand for CAR. Nuclear CAR heterodimerizes to
the retinoid X receptor (RXR) and positively regulates gene
expression by binding to the PB-responsive enhancer module
(PBREM) located on the upstream region of the target genesAbbreviations: 2-AAF, 2-acetylaminoﬂuorene; CAR, constitutive
androstane receptor; CCRP, cytosolic CAR retention protein; CYP,
cytochrome P450; GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase; GFP, green ﬂuorescent protein; GSTp, placenta form of glutat-
hione S-transferase; PB, phenobarbital; PBREM, PB-responsive
enhancer module; PROD, 7-pentoxyresoruﬁn-O-dealkylase; RXR,
retinoid X receptor; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]
benzene
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doi:10.1016/j.febslet.2005.05.028[2]. Therefore, nuclear translocation of this transcription factor
is a key event in its transactivating function. Although, it has
been reported that phosphorylation is involved in this transac-
tivation [4,5], this result by itself is still far from accounting for
the entire machinery governing the activation process of CAR,
including the changes in the cytoplasmic anchor and the driv-
ing force of the nuclear translocation.
Constitutive levels and the inducibility of CYPs are altered
under pathophysiological conditions. In experimental animals,
it has been reported that PB induction of CYP2B is attenuated
in preneoplastic lesions [6,7]. However, the molecular basis
for the reduced CYP induction in tumor tissues is inadequately
understood. The present study provides evidence for an
impaired nuclear translocation of CAR in response to PB
administration in the liver of rats subjected to chemical carci-
nogenesis. These observations suggest an alteration of CAR
function is associated with the resistance of CYP2B induction
seen during liver carcinogenesis.2. Materials and methods
2.1. Materials
Anti-CYP2B1 antibody and the anti-placenta form of glutathione
S-transferase (GSTp) were purchased from Daiichi Pure Chemicals
and MBL Co. (Nagoya, Japan), respectively. Rabbit anti-rat CAR
polyclonal antibody was raised against a peptide (SPDRPGVTQRE-
EIDQLQE) conjugated with keyhole limpet hemocyanin and was puri-
ﬁed with the aﬃnity resin.
2.2. Animals
All experiments were conducted under NIH guidelines for the care
and use of laboratory animals and were approved by the Showa Uni-
versity Institutional Animal Care and Use Committee. Male F344
rats (4 weeks of age) and male C3H/HeN mice (3 weeks of age) were
purchased from Japan SLC, Inc. The modiﬁed Solt-Farber model of
hepatocarcinogenesis in rats has been described elsewhere [7,8].
Brieﬂy, at 5 weeks of age (day 0), rats received N-nitrosodiethylamine
(200 mg/kg, ip.). From day 18 to day 20 and day 22, rats were admin-
istered 2-acetylaminoﬂuorene (2-AAF) (20 mg/kg/day, po.). On day
21, rats were administered carbon tetrachloride (1.5 ml/kg, po.). Rats
were sacriﬁced 4-week after the ﬁnal 2-AAF treatment. A similar
protocol was applied to mice as well. Mice at 4 weeks of age were
administered N-nitrosodiethylamine (90 mg/kg, ip.) on day 0,
2-AAF (20 mg/kg/day, po.) from day 40 to day 42 and day 46 and
carbon tetrachloride (1.5 ml/kg, po.) on day 44. Mice were sacriﬁced
on day 74. The respective control animals (normal group) were pur-
chased simultaneously with and bred in cages next to the animal
group subjected to the protocol for carcinogenesis. Animals were
administered intraperitoneally with PB (80 mg/kg for rats and
100 mg/kg for mice, respectively) 24 h before sacriﬁce. Animals were
starved 16 h before sacriﬁce.blished by Elsevier B.V. All rights reserved.
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Microsomal CYP content and 7-pentoxyresoruﬁn-O-dealkylase
(PROD) activity were determined by CO-diﬀerential spectrum [9]
and by resoruﬁn production from 7-pentoxyresoruﬁn during a 10-
min incubation, respectively. Liver nuclear extracts were prepared
using NE-PER nuclear extraction reagents (Pierce Biotechnology,
Inc., Rockford, IL) essentially according to the manufacturers instruc-
tions. Immunoblot analysis was carried out as described [10] using 20
or 2 lg for nuclear or microsomal fraction, respectively. Total RNA
(20 lg) isolated from frozen liver samples was subjected to Northern
blot analysis as described previously [10]. The probes used were the
1.25 kb PstI insert puriﬁed from rat pcP-450pb1 plasmid (Riken Bio-
Resource Center, Ibaraki, Japan) for rat CYP2B1/2, oligoDNA
(TTCCTTGAAGGTTGGCTCAACGACAGCAACT) for mouse
Cyp2b10 and the 0.5 kb insert of a glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) cDNA puriﬁed from GD5 plasmid [11]. CYP2B
mRNA levels were normalized to the respective GAPDH expressions.
2.4. Transfection of a GFP-CAR construct
A rat CAR cDNA fragment corresponding to amino acid residues
2–358 was PCR ampliﬁed by high ﬁdelity enzyme HF2 (BD Biosci-
ences, Clonetech, Palo Alto, CA) using a rat liver cDNA library as a
template and inserted in-frame into a pQBI25 vector (Wako, Tokyo,
Japan) to generate CAR/pQBI25 that expresses the green ﬂuorescent
protein (GFP) fused to the amino terminal of CAR. The primers for
the PCR were 5 0-CGCGGATCCACAGCTACTCTAACACTAGA-
GACC-30 and 5 0-CGGAATTCTCAGCTGCAAATCTCCCCAAG-
CAG-30. C3H mice were transfected with 10 lg of CAR/pQBI25 via
the tail vain using the TransIT in vivo gene delivery system (Mirus,
Madison, WI). Liver sections were ﬁxed with 4% paraformaldehyde
and mounted along with 4 mg/ml 4 0,6-diamidino-2-phenylindole
(DAPI). The image was acquired on a ﬂuorescent microscope (Key-
ence BZ-8000).0
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**2.5. Reporter assay
For construction of the PBREM/pTAL-Luc reporter plasmid used
in the luciferase assay, a double strand DNA fragment containing
51 bp PBREM of rat CYP2B1 gene [12] was produced by PCR using
the primers 5 0-GGGGTACCTCTGTACTTTCCTGACCTTGGCAC-
AGTGCCACCATC-3 0 and 5 0-GCTCTAGAGGTGTCAGTCAA-
GTTGATGGTGGCACTGTGCCAAG-3 0 (possessing the underlined
20 bp overlapping sequence) and inserted upstream of the TATA-like
promoter in a pTAL-Luc vector (BD Biosciences). Mice were intrave-
nously injected with 8 lg of PBREM/pTAL-Luc along with 2 lg of a
Renilla luciferase expression vector pRL-TK (Promega, Madison,
WI) using the TransIT in vivo gene delivery system (Mirus Bio, Mad-
ison, WI). After 24 h mice were sacriﬁced and livers were homogenized
in 20 vol of a passive lysis buﬀer (Promega). The homogenate was cen-
trifuged at 15000 rpm for 15 min and the resulting supernatant was
used for the dual luciferase assay system (Promega). Fireﬂy luciferase
activity was normalized to the respective Renilla luciferase activity.0
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Fig. 1. Suppressed induction of CYP2B by PB during hepatocarcino-
genesis. The normal or adenocarcinoma group of rats were either
treated with saline or PB 24 h before sacriﬁce. CYP contents, CYP2B
mRNA and protein levels and PROD activity in the liver were
determined. The CYP2B mRNA and protein levels are illustrated as a
percent of the saline-treated normal rats. The results represent the
means + S.E. of 3–4 rats. The signiﬁcance of diﬀerence was assessed by
ANOVA followed by Scheﬀes F test (\P < 0.05, \\P < 0.01,
\\\P < 0.001).3. Results
3.1. Attenuation of CYP2B induction in tumors
Using an experimental model of hepatocarcinogenesis
based on a modiﬁed Solt-Farber protocol [7,8], rats (the
adenocarcinoma group) exhibited diﬀuse hyperplastic nod-
ules/foci in the liver, which were observable as early as
one-week after the last 2-AAF treatment, and both the mass
and number increased by week 4 (data not shown). PB-med-
iated CYP induction in the liver of the adenocarcinoma
group was examined. Four weeks after the ﬁnal 2-AAF
treatment, rats were administered PB 24 h before sacriﬁce.
In the normal group, single PB administration induced a
moderate increase in CYP content 24 h later (124% of the
untreated normal rats), but did not induce the content in
the adenocarcinoma group (86% of the untreated adenocar-
cinoma group, Fig. 1). On the other hand, the CYP contentin the PB-treated adenocarcinoma group was signiﬁcantly
lower (P = 0.0157) than that in the PB-treated normal
group. Northern and immunoblot analyses were conducted
to examine the responses of CYP2B, which is the most
inducible isoform by PB administration in rats. These anal-
yses revealed the induction of both the CYP2B mRNA and
protein levels by PB, which were observed signiﬁcantly in
the normal group, were attenuated in the adenocarcinoma
group (Fig. 1). Furthermore, PB-mediated induction of
PROD activity, a selective marker for CYP2B, was consider-
ably suppressed in the adenocarcinoma group (Fig. 1).
PB-induced levels of PROD activity in the adenocarcinoma
group were not signiﬁcant (P = 0.118) compared to the
respective untreated controls.
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Attenuation of the CYP induction by PB in the hepatic neo-
plastic lesions suggested that CAR functions had been altered.
Therefore, the PB-mediated CAR response, namely the intra-
cellular distribution of the nuclear receptor, was tested by
means of immunoblot analysis with the hepatic nuclear frac-
tions obtained from the normal and adenocarcinoma groups
(Fig. 2A). In the untreated normal rats, low levels of CAR
in the nuclear fraction were observed. Upon PB treatment,
the band intensity of CAR in the nuclear fraction increased.
On the other hand, the band intensity of nuclear CAR scarcely
increased in the PB-treated adenocarcinoma group (Fig. 2A).Fig. 2. Impaired nuclear translocation of CAR in hepatic pleneoplastic legio
The nuclear fractions were subjected to immunoblot analysis using anti-CA
followed by Scheﬀes F test (\P < 0.05). (B) C3H mice were subjected to the
groups of mice were transfected with a PBREM/pTAL-Luc along with pRL
homogenate was centrifuged and obtained supernatant was subjected to im
luciferase assay (lower panel). GSTp expressions were normalized with respe
illustrated as a percent of the saline treated normal group of mice. The signiﬁc
(\\\P < 0.001). (C) The normal or the adenocarcinoma group of mice were
Cyp2b10 mRNA levels determined by Northern blot analysis are illustrated
means + S.E. of 3–5 mice. The signiﬁcance of diﬀerence was assessed by ANO
(D) The normal or the adenocarcinoma group of mice transfected with CAR
4 h after the transfection (PB). Mice were sacriﬁced 16 h after transfectio
Representative cells are shown for each group with green ﬂuorescence fro
localization of the GFP-CAR in transfected hepatic cells was scored for at l
distribution; N = C, equal distribution to the nuclear and cytoplasmic compa
3–4 mice (lower panel).To obtain further information on the function of CAR in
the CYP2B expression of the adenocarcinoma group, the
transactivation of PBREM was examined in vivo. In these
experiments, mice were used instead of rats because of the
ease of in vivo transfection in this animal model. C3H mice
were subjected to the resistant hepatocyte model of carcino-
genesis similar to that applied to rats. Although these mice
showed no obvious hyperplastic nodules in the liver speci-
men, the hepatic GSTp levels determined by immunoblot
analysis were signiﬁcantly induced (Fig. 2B). Therefore, the
hepatic preneoplastic lesions were considered as established
by the protocol used in this study. Moreover, Northern blotns. (A) The normal and the adenocarcinoma rats were treated with PB.
R antibody. The signiﬁcance of diﬀerence was assessed by ANOVA
protocol for hepatocarcinogenesis. The normal and adenocarcinoma
-TK plasmid and simultaneously treated with PB for 12 h. The liver
munoblot analysis using anti-GSTp antibody (upper panel) or dual
ctive GAPDH expression. GSTp expression and luciferase activity are
ance of diﬀerence was assessed by ANOVA followed by Scheﬀes F test
either treated with saline or 100 mg/kg PB 6 h before sacriﬁce. The
as a percent of the saline-treated normal mice. Results represent the
VA followed by Scheﬀes F test (\P < 0.05, \\P < 0.01, \\\P < 0.001).
/pQBI25 were either untreated (Control) or treated with 100 mg/kg PB
n. Liver sections were investigated under a ﬂuorescent microscopy.
m GFP and blue ﬂuorescence from DAPI (upper panel). Subcellular
east 200 cells and classiﬁed into 3 categories: C, cytoplasmic dominant
rtments; N, nuclear dominant distribution. Data represent the mean of
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gene expression in the adenocarcinoma group of mice (Fig.
2C), as had been observed in the respective rat model. Using
these animals, a reporter vector, which was constructed by
insertion of the 51 bp-PBREM enhancer of the rat CYP2B1
gene [12] upstream of the thymidine kinase promoter, was
transfected in vivo by tail vein injection and the PB-medi-
ated response was examined (Fig. 2B). When PB was admin-
istered to the normal group, a signiﬁcant increase in the
reporter activity was observed, indicating that the exoge-
nously introduced enhancer was activated in a PB-dependent
manner. In contrast, treatment of mice subjected to the pro-
tocol for hepatocarcinogenesis exerted virtually no inﬂuence
on the PBREM-reporter activity (Fig. 2B).
Because ectopic expression of CAR in cultured cells such as
HepG2 hepatoma cells results in the nuclear distribution of
the gene product [4], we tested the PB responsiveness
of CAR by using mice transfected with the GFP-fused rat
CAR construct (Fig. 2D). In the normal mice, the GFP-
CAR fusion proteins were mainly distributed in the cytoplasm
and translocated to the nuclear compartment in response to
PB, indicating that this experimental model reﬂects the distri-
bution of endogenous CAR. On the other hand, most of the
transfected hepatocytes in the adenocarcinoma group retained
the fusion protein in the cytoplasm in spite of PB treatment
(Fig. 2D).4. Discussion
Attenuation of PB-mediated CYP2B induction in experi-
mental animal hepatic tumor tissue has been demonstrated
by immunohistochemical analysis [6,7]. The attenuated re-
sponses to PB treatment in hepatic CYP2B mRNA and pro-
tein as well as in PROD activity in the rat adenocarcinoma
group presented in this study are consistent with previous re-
ports [6,7]. Taken together, it is possible that a decrease in
the PB responsiveness of CYP2B is the result of impaired
transactivation of the CYP2B gene. In consideration of the
fact that we used a whole liver specimen for the measurement
of the mRNA, protein and activity of the CYP enzymes, it is
suggested that there is much less PB-mediated responsiveness
in the transcription of the CYP2B gene in the hyperplastic
nodules.
The initial concern was that restricted expression of CAR
might be involved in the restricted PB induction of CYP2B.
However, hepatic CAR expression in the adenocarcinoma
group did not decrease but rather was enhanced (Maruyama,
Numazawa and Yoshida, unpublished results). Because CAR
activates target genes in a ligand-independent manner, the
failure of CYP2B induction implies modiﬁcation of the func-
tionality of CAR. As demonstrated in this study by immuno-
blot analysis, cellular distribution of GFP-CAR and
transactivation of PBREM in vivo, it is strongly suggested
that the nuclear translocation of CAR in response to PB is im-
paired in the adenocarcinoma group. Along these lines, it has
been reported that CYP2B induction by 1,4-bis[2-(3,5-dichlo-
ropyridyloxy)]benzene (TCPOBOP), the most potent known
member of the PB-like class of CYP-inducing agents, was
attenuated in RXRa null mice [13]. However, the nuclear
RXRa levels in the liver were constant during hepatocarcino-genesis in this study (data not shown). This body of data indi-
cates the failure of CYP2B induction in hepatic tumors is
apparently a consequence of the impaired nuclear transloca-
tion of CAR that occurs during carcinogenesis. However,
on the other hand, when PB-mediated responses of CAR nu-
clear translocation and PBREM transactivation disappeared,
suppressed but signiﬁcant levels of CYP2B induction by PB
were observed in tumor-bearing animals. Because CAR and
the pregnane X receptor (PXR), another nuclear receptor
implicated in xenobiotic metabolism, have cross talk with
each other [14], the PXR-mediated machinery appears to be
partly involved in the PB induction of CYP2B in the tumor-
bearing animals.
Recently, it has been demonstrated using genetically modi-
ﬁed mice that CAR plays a pivotal role in tumor promoter
activity of PB [15]. These observations suggest that continuous
activation of CAR and expression of its target gene are impor-
tant for PB-mediated tumor promotion. It is important to
note that CAR functionality is likely preserved during early
stage of hepatocarcinogenesis. Accordingly, the modulation
of CAR function during hepatocarcinogenesis demonstrated
could be a protective response of the animals against chemical
carcinogens. The pathophysiological roles of this transcription
factor will need to be further clariﬁed with these ﬁndings in
mind.
It is assumed that CAR function is controlled either
directly by an agonist ligand such as TCPOBOP [16] or indi-
rectly by inducers, including PB [2,4,17]. TCPOBOP-
mediated activation is explained by analogy to the PXR,
which activation requires ligand binding. In contrast, the
mechanisms that confer PB-mediated nuclear translocation
of CAR, a key step in the transactivation of target genes,
are still inadequately understood at present. Recently, the
cytosolic CAR retention protein (CCRP) that regulates the
cytosolic distribution of CAR by forced expression in cul-
tured cells has been identiﬁed [18]. It has been postulated that
CCRP plays a role as a co-chaperone that joins the HSP90
chaperone protein to CAR by binding the ligand binding do-
main of the nuclear receptor. In addition, because geldana-
mycin, which suppresses HSP90 function by binding the
ATP/ADP binding site in the chaperone, and the protein
phosphatase inhibitor okadaic acid both inhibit nuclear
translocation of CAR, phosphorylation/dephosphorylation
might be crucially involved in the release of CAR from the
CAR/CCRP/HSP90 complex in the cytoplasm [4,5,19]. In-
creased protein phosphorylation levels are often observed in
tumors, suggesting these steps might be involved in the re-
stricted nuclear translocation of CAR. Further study is now
underway in an eﬀort to clarify the detailed mechanisms of
the impaired nuclear translocation of CAR during carcino-
genesis observed in this study.
In conclusion, the present study demonstrates that the
modulation of nuclear receptor function under pathological
conditions is able to suppress expression of the target gene.
Chemical carcinogenesis in experimental animals will be cru-
cial to obtain an elucidation of the mechanistic regulation
of CAR function, including the step of nuclear transloca-
tion. Moreover, although impaired CAR function in pa-
tients remains to be formally demonstrated, the results
obtained here provide valuable information towards the
ability to predict drug–drug interactions under pathological
conditions.
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